image
Healthcare - Medical - Devices - NASDAQ - US
$ 13.78
0.9 %
$ 326 M
Market Cap
19.21
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TCMD stock under the worst case scenario is HIDDEN Compared to the current market price of 13.8 USD, Tactile Systems Technology, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TCMD stock under the base case scenario is HIDDEN Compared to the current market price of 13.8 USD, Tactile Systems Technology, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TCMD stock under the best case scenario is HIDDEN Compared to the current market price of 13.8 USD, Tactile Systems Technology, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TCMD

image
$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
293 M REVENUE
6.76%
22.2 M OPERATING INCOME
22.95%
17 M NET INCOME
-40.52%
40.7 M OPERATING CASH FLOW
13.39%
-2.5 M INVESTING CASH FLOW
-0.64%
-4.82 M FINANCING CASH FLOW
-84.19%
85.6 M REVENUE
17.09%
12.5 M OPERATING INCOME
84.56%
9.72 M NET INCOME
88.48%
16.3 M OPERATING CASH FLOW
59.25%
-492 K INVESTING CASH FLOW
49.69%
-3.62 M FINANCING CASH FLOW
-382.67%
Balance Sheet Tactile Systems Technology, Inc.
image
Current Assets 178 M
Cash & Short-Term Investments 109 M
Receivables 44.9 M
Other Current Assets 23.7 M
Non-Current Assets 120 M
Long-Term Investments 0
PP&E 22.2 M
Other Non-Current Assets 98.1 M
36.56 %15.08 %7.96 %7.46 %32.94 %Total Assets$297.9m
Current Liabilities 40.7 M
Accounts Payable 5.65 M
Short-Term Debt 2.98 M
Other Current Liabilities 32.1 M
Non-Current Liabilities 40.6 M
Long-Term Debt 16 M
Other Non-Current Liabilities 24.7 M
6.94 %3.66 %39.44 %19.62 %30.33 %Total Liabilities$81.3m
EFFICIENCY
Earnings Waterfall Tactile Systems Technology, Inc.
image
Revenue 293 M
Cost Of Revenue 102 M
Gross Profit 191 M
Operating Expenses 192 M
Operating Income 22.2 M
Other Expenses 5.22 M
Net Income 17 M
300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)293m(102m)191m(192m)22m(5m)17mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
65.26% GROSS MARGIN
65.26%
7.57% OPERATING MARGIN
7.57%
5.79% NET MARGIN
5.79%
7.83% ROE
7.83%
5.69% ROA
5.69%
6.16% ROIC
6.16%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tactile Systems Technology, Inc.
image
40m40m35m35m30m30m25m25m20m20m15m15m10m10m5m5m00(5m)(5m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 17 M
Depreciation & Amortization 6.8 M
Capital Expenditures -2.51 M
Stock-Based Compensation 7.82 M
Change in Working Capital 7.71 M
Others -3.94 M
Free Cash Flow 38.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tactile Systems Technology, Inc.
image
Wall Street analysts predict an average 1-year price target for TCMD of $16 , with forecasts ranging from a low of $16 to a high of $16 .
TCMD Lowest Price Target Wall Street Target
16 USD 16.11%
TCMD Average Price Target Wall Street Target
16 USD 16.11%
TCMD Highest Price Target Wall Street Target
16 USD 16.11%
Price
Max Price Target
Min Price Target
Average Price Target
2020191918181717161615151414131312121111Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Tactile Systems Technology, Inc.
image
Sold
0-3 MONTHS
810 K USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
20.3 K USD 1
9-12 MONTHS
88.5 K USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Tactile Medical to Release First Quarter of Fiscal Year 2025 Financial Results on May 5, 2025 MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2025 financial results will be released after the market closes on Monday, May 5, 2025. globenewswire.com - 1 week ago
Tactile Medical to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference MINNEAPOLIS, March 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference, which is being virtually held from March 17th – 20th. Management will participate in a virtual presentation on Tuesday, March 18th at 12:00 p.m. Eastern Time. globenewswire.com - 1 month ago
Tactile Systems Technology, Inc. (TCMD) Q4 2024 Earnings Call Transcript Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q4 2024 Earnings Conference Call February 18, 2025 5:00 PM ET Company Participants Sam Bentzinger - Investor Relations, Gilmartin Group LLC Sheri Dodd - Chief Executive Officer Elaine Birkemeyer - Chief Financial Officer Conference Call Participants Max Smock - William Blair Adam Maeder - Piper Sandler Iseult McMahon - BTIG Kyle Bauser - B. Riley Securities Suraj Kalia - Oppenheimer & Company Operator Please standby. seekingalpha.com - 2 months ago
Tactile Systems Technology (TCMD) Tops Q4 Earnings and Revenue Estimates Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.40 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.38 per share a year ago. zacks.com - 2 months ago
Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 2 months ago
Tactile Medical to Release Fourth Quarter and Fiscal Year 2024 Financial Results on February 18, 2025 MINNEAPOLIS, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2024 financial results will be released after the market closes on Tuesday, February 18, 2025. globenewswire.com - 2 months ago
Tactile Medical Appoints Laura King to Board of Directors MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Laura King to the Company's Board of Directors (“Board”) and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. globenewswire.com - 3 months ago
Is Tactile Systems Technology (TCMD) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 4 months ago
TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell? Tactile Systems' top line reflects strong demand for its existing products. Workflow enhancements are driving efficiency. zacks.com - 4 months ago
Should Value Investors Buy Tactile Systems Technology (TCMD) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 4 months ago
Are Investors Undervaluing Tactile Systems Technology (TCMD) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 5 months ago
Tactile Systems Technology, Inc. (TCMD) Hit a 52 Week High, Can the Run Continue? Tactile Systems Technology (TCMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 5 months ago
8. Profile Summary

Tactile Systems Technology, Inc. TCMD

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 326 M
Dividend Yield 0.00%
Description Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Contact 3701 Wayzata Boulevard, Minneapolis, MN, 55416 https://www.tactilemedical.com
IPO Date July 28, 2016
Employees 1037
Officers Ms. Elaine M. Birkemeyer Chief Financial Officer Mr. Jerry A. Sauber Senior Vice President of Manufacturing, Operations, R&D Aaron R. Snodgrass Senior Vice President of Sales Mr. Daniel L. Reuvers Director & Advisor Ms. Kristie T. Burns Senior Vice President of Marketing & Clinical Affairs Ms. Sheri Louise Dodd Chief Executive Officer, President & Director Dr. Antonios P. Gasparis F.A.C.S., M.D. Chief Medical Officer & Member of Vascular Strategic Advisory Board Mr. John David Kaercher Chief Information Officer Ms. Sunday J. Hoy Esq. Vice President of Regulatory Affairs & Chief Compliance Officer Janelle M. Strop Chief Human Resource Officer